MarginsXMarginsX
Home › Markets › Health Care › NMRA

Neumora Therapeutics Inc. (NMRA)

NMRA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3695
-13.85% on the day
Market cap
$69.4M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerNMRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2023
SEC CIK0001885522
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
7.8 months
$116.8M cash at June 30, 2026
Share count, 1 year
+16.0%
2025-08-01 to 2026-08-10 · +23.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$3.9M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern."
10-Q 2026-08-14
Cash and burn$116.8M cash; operating cash flow -$45.1M a quarter.Report 2026-06-30
Shares outstanding187,895,912 (2026-08-10); 161,945,427 a year earlier; 152,703,316 three years earlier.Cover page 2026-08-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-10-30
AuditorErnst & Young LLP, San Jose, California, United StatesPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5.0M, sold $1.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$43.1M-$39.5M$116.8M$52.9MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$53.5M-$46.4M$147.1M$53.0MNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$59.5M-$48.0M$182.5M$54.5MNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$56.8M-$46.6M$129.1M$19.6MNeeds four quarters10-Q 2025-11-06
Q2 2025
2025-06-30
Not filed-$52.7M-$52.4M$124.5M$19.5MNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$68.0M-$59.4M$126.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$58.8M-$50.3M$142.1M$0Needs four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$72.5M-$33.5M$275.7MNo debt tagsNeeds four quarters10-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2025-03-03
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-08-14
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 259 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.7%
1 month+15.9%
3 months-75.2%
Year to date-76.0%
1 year-84.1%
From 52-week high-88.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
AVXLAnavex Life Sciences Corp.$0.8176-12.42%$75.8M
TNYATenaya Therapeutics Inc.$0.3336-4.47%$76.0M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M
CHRSCoherus Oncology Inc.$0.5059-3.73%$78.2M
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier